Bicara Therapeutics (BCAX) vs Harrow (HROW)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Bicara Therapeutics (BCAX) has outperformed Harrow (HROW) over the past year, losing 9.6% versus a loss of 26.9%. Harrow is the larger company by market cap ($1.14 billion vs $1.14 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCAX | HROW |
|---|---|---|
| Share price | $17.26 | $30.52 |
| Market cap | $1.14B | $1.14B |
| 1-day change | +5.12% | -0.33% |
| YTD return | -2.44% | -37.51% |
| 1-year return | -9.63% | -26.92% |
| 5-year return | — | +209.61% |
| Forward P/E | — | 11.01 |
| EPS (TTM) | $-3.08 | $-0.99 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $30.99 | $54.85 |
| 52-week low | $13.70 | $28.54 |
| Distance from 52-week high | -44.30% | -44.36% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +105.68% | +112.98% |
| Average volume | 610.46K | 555.14K |
| Shares outstanding | 66.17M | 37.49M |
| Employees | 103 | 373 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BCAX has outperformed HROW by 17.3 percentage points over the past year.
About Bicara Therapeutics
BCAX stock →Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 103 employees
About Harrow
HROW stock →Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 373 employees
BCAX vs HROW FAQ
Which is bigger, Bicara Therapeutics or Harrow?
Harrow (HROW) is larger, with a market capitalization of $1.14B compared with $1.14B for Bicara Therapeutics (BCAX).
Which stock has performed better over the past year, BCAX or HROW?
BCAX returned -9.63% over the past 12 months, compared with -26.92% for HROW (price return, excluding dividends). Past performance does not predict future results.
Are Bicara Therapeutics and Harrow in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.